Get started
Author

Monica Niger

Observed names: M. Niger, Niger Monica, Niger, M., Niger, Monica
ORCID: 0000-0002-9055-5338
Observed ORCID: 0000-0002-9055-5338
OpenAlex ID: A5030318941
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair
2018 · Parker L. Sulkowski, Ranjini K. Sundaram, et al. · Nature Genetics · 212
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
2024 · Federico Nichetti, Simone Rota, et al. · JAMA Network Open · 136
PDF
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
2022 · Federica Morano, Alessandra Raimondi, et al. · Journal of Clinical Oncology · 130
PDF
Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
2018 · Francesca Corti, Federico Nichetti, et al. · Cancer Treatment Reviews · 128
Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review
2016 · Dario Baratti, Shigeki Kusamura, et al. · Critical Reviews in Oncology/Hematology · 123
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
2019 · Sara Pusceddu, Michele Ghidini, et al. · Cancers · 117
PDF
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
2023 · Margherita Rimini, Lorenzo Fornaro, et al. · Liver International · 113
PDF
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer
2019 · Filippo Pietrantonio, Federica Morano, et al. · JAMA Oncology · 113
PDF
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO
2024 · A. Raimondi, S. Lonardi, et al. · Annals of Oncology · 100
PDF
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
2023 · Julien Taïeb, Lina Sayah, et al. · European Journal of Cancer · 99
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
2025 · Jesus M. Banales, Pedro M. Rodrigues, et al. · Nature Reviews Gastroenterology & Hepatology · 85
PDF
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
2019 · Giovanni Randon, Giovanni Fucà, et al. · Scientific Reports · 68
PDF
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
2024 · Margherita Rimini, Lorenzo Fornaro, et al. · European Journal of Cancer · 58
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial
2019 · Maria Di Bartolomeo, Federica Morano, et al. · The Oncologist · 57
Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.
2015 · Filippo G. De Braud, Monica Niger, et al. · Journal of Clinical Oncology · 52
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
2016 · Filippo Pietrantonio, Rosa Berenato, et al. · Journal of Translational Medicine · 46
PDF
The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review
2021 · Carlo Sposito, Michele Droz dit Busset, et al. · European Journal of Surgical Oncology · 42
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy
2015 · Luigi Celio, Monica Niger, et al. · Core evidence · 39
PDF
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
2021 · Raghav Sundar, Kie-Kyon Huang, et al. · Gut · 37
PDF
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation
2018 · F. Morano, S. Corallo, et al. · Annals of Oncology · 37
PDF
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
2018 · Maria Di Bartolomeo, Monica Niger, et al. · Targeted Oncology · 37
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
2017 · Daniele Oddo, Giulia Siravegna, et al. · British Journal of Cancer · 36
PDF
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
2015 · Filippo Pietrantonio, Giuseppe Aprile, et al. · Radiotherapy and Oncology · 34
Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases
2020 · Dario Baratti, Shigeki Kusamura, et al. · Annals of Surgical Oncology · 33
The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence
2020 · Sara Pusceddu, Claudio Vernieri, et al. · Therapeutic Advances in Gastroenterology · 33
PDF
Works count: 308
Citation count: 3,084
H-index: 29
I10-index: 72
Year
Topic
Type